Adhering to the dual drive of "technical innovation" and "clinical value", with "new markers / underlying technologies / key raw materials / automatic instruments” research and development and industrialization as the core, is committed to providing innovative solutions for the diagnosis of malignant tumors, neurodegenerative diseases and major infectious diseases!
20+ exclusive diagnostic products have been developed, 6 Class III products have been approved for marketing, 2 Class II products (technical authorization) have been approved for marketing, 2 Class II instruments have been approved for marketing, 5 are under NMPA registration review, 7 During 2022-2023, it is planned to start domestic registration clinical trials of 10+ new products, of which >3 products have achieved registration applications in the United States and other countries.